CD Skripsi
Sintesis, Molecular Docking Dan Uji Bioaktivitas Hidrazon (E)-N’-((E)-3-(4-Metoksifenil)-1-(Naftalen- 1-Il)Alliliden)-4-Metilbenzensulfonohidrazid Sebagai Antikanker
SUMMARY
Hydrazone is a stable amine-type substitution product that has a basic structure
(R1-HC=N-NH-R2). Hydrazone compounds have an izometine group that play an
important role in their biological activities, such as antitumor and anticancer
agent. In this study the compound (E)-N'-((E)-3-(4-methoxyphenyl)-1-
(naphthalen-1-yl)allylidene)-4-methylbenzensulfonohidrazide has been
successfully synthesized with several steps of reaction. The reaction begins with
formation of chalcone (E)-3-(4-methoxyphenyl)-1-(naphtalene-1-yl)-prop-2-en-1-
one by condensing 1-acetylnaphtalene with 4-methoxybenzaldhyde using KOH
3N as catalysts via microwave irradiation at 180 W. The next step was reacted
chalcone and p-toluensulfonyl hydrazine with HCl 3N as catalyst. The target
compound synthesis used stirrer and heated with preassure then produced yield
77.87%. The purity of the hydrazone compound was determined using the TLC
(thin-layer chromatography), melting point and HPLC (high-performace liquid
chromatography) analysis. The structure of hydrazone compound was confirmed
by UV (ultraviolet), FTIR (fourier-transform infrared), 1H-NMR, 13C-NMR
(nuclear magnetic resonance), and HRMS (high resolution mass spectrometry).
Molecular docking studies were carried out against estrogen-α receptors
(PDB ID:3ERT) and SIRT 1 (PDB ID:4I5I). The results of molecular docking
studies obtained free energy bond ΔGbind = -11.33 kcal/mol against estrogen-α and
ΔGbind = -14.67 kcal/mol against SIRT 1 which showed that the hydrazone
compound had good activity as an inhibitor against of the both cancers. The
results of the in vitro studies showed that the hydrazone compound was non-toxic
with LC50 value of 251.18 μg/mL.
Tidak tersedia versi lain